Therapeutic effects of If blockade: Evidence and perspective

Pharmacological Research

Volumn 53, Issue 5, 2006, Pages 440-445

  Borer, Jeffrey S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angina pectoris; Coronary artery disease; Ischemia

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FUNNY CHANNEL; GLYCERYL TRINITRATE; ION CHANNEL; IVABRADINE; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANGINA PECTORIS; ARTICLE; BLURRED VISION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; HYPOTENSION; PRIORITY JOURNAL; RETINA INJURY; SINUS NODE; SYNCOPE; TREATMENT OUTCOME; VISUAL DISORDER;

ANGINA PECTORIS; ANIMALS; BENZAZEPINES; HEART RATE; HUMANS; ION CHANNELS; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646719668     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.017     Document Type: Article

References (31)

1. Brown H.F., DiFrancesco D., and Noble S.J. How does adrenaline accelerate the heart?. Nature 280 (1979) 235-236
2. f) induced by acetylcholine in rabbit sino-atrial node myocytes. J Physiol (Lond) 405 (1988) 477-491
3. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 434 (1991) 23-40
4. Thollon C., Cambarrat C., Vian J., et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea pig-cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 112 (1994) 37-42
5. Simon L., Ghaleh B., Puybasset L., et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharm Exp Therap 275 (1995) 659-666
6. Colin P., Ghaleh B., Monnet X., et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282 (2002) H672-H679
7. Moore N., Joannides R., Iacob M., et al. Effects of a pure bradycardic agent S 16257, at rest and during exercise in healthy volunteers: comparison with propranolol. Br J Clin Pharm 45 (1998) 188-189
8. Manz M., Reuter M., Lauck G., et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003) 149-155
9. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
10. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
11. Gibbons R.J., Chatterjee K., Daley J., et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 99 (1999) 2829-2848
12. Williams S.V., Fihn S.D., and Gibbons R.J. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification. Ann Intern Med 135 (2001) 530-547
13. Pepine C.J., Abrams J., Marks R.G., et al. Characteristics of a contemporary population with angina pectoris: TIDES Investigators. Am J Cardiol 74 (1994) 226-231
14. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 3rd ed. (1988), W.B. Saunders, Philadelphia p. 1330
15. Epstein S.E., Beiser G.D., Goldstein R.E., Redwood D., Rosing D.R., Glick G., et al. Treatment of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med 280 (1969) 971-978
16. Frishman W.H., and Sica D.A. Calcium channel blockers. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular pharmacotherapies. 2nd ed. (2003), McGraw-Hill, New York 105-130
17. Borer J.S. Development of cardiovascular drugs: the US regulatory milieu from the perspective of a participating non-regulator. J Am Coll Cardiol 44 (2004) 2285-2292
18. Lipicky R.J. Natural history endpoints and angina trials. In: Borer J.S., and Somberg J.C. (Eds). Cardiovascular drug development: protocol design and methodology (1999), Marcel Dekker, New York 185-187
19. Borer JS (moderator). Development of antilipid and anti-ischemic therapy: panel discussion. In: Borer JS, Somberg JC, editors. Cardiovascular drug development: protocol design and methodology. New York: Marcel Dekker; 1999. pp. 197-211.
20. f inhibitors as specific heart rate reducing agents. Nat (Clin Pract Cardiovasc) 1 (2004) 103-109
21. f inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
22. f inhibitor compared with atenolol in patients with chronic stable angina. Eur Heart J 26 (2005) 2529-2536
23. f current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial. Eur Heart J 25 Suppl. (2004) 138
24. f current inhibitor ivabradine in patients with chronic stable angina. A 1 year randomised, double-blind, multicentre trial. Eur Heart J 25 Suppl. (2004) 138
25. Heidland U.E., and Strauer B.E. Left ventricular muscle mass and elevated heart-rate are associated with coronary plaque disruption. Circulation 104 (2001) 1477-1482
26. Kjekshus J., and Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1 Suppl. H (1999) H64-H69
27. Kjekshus J.K. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial intervention trials. Am J Cardiol 57 (1986) 43F-49F
28. Diaz A., Bourassa M.G., Guertin M., et al. Eur Heart J 26 (2005) 967-974
29. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109 (2004) 1674-1679
30. Manz M., Reuter M., Lauck G., et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003) 149-155
31. Borer J.S. Heart rate reduction: a therapeutic target in cardiovascular disease. Adv Heart Rate Reduction 1 (2004) 1-3